Aestis is currently raising $1.25 million in seed financing to fund preclinical trials. The trials will be a blinded study with c.a. 30 subjects and 30 controls with a hypoxic exposure period of 3-4 weeks. $300,000 will be used for equipment, $700,000 for site study costs and $250,000 for the company’s study costs, including consultant fees. These studies are expected to be completed in nine months. Series A financing will be raised upon completion of the preclinical trials. Qualified investors are invited to review the company’s business plan.